Combining Dalantercept and Axitinib for Advanced Kidney Cancer

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the phase I/II DART study.

Clinical Pearls

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the phase I/II DART study. The study compareddalantercept plus axitinib with placebo plus axitinib for patients with advanced clear cell renal cell carcinoma.

  • Dose-determining toxicities for dalantercept were fluid retention and anemia.
  • No additive toxicity was observed. The combination was well tolerated, even at the highest dose levels.
  • Median PFS was approximately 8 months for the entire study population.
  • Median PFS has not yet been reached among patients receiving the dose chosen for part II of the study.